I am joining the chorus with the positive outlook.
IMO The current management team have the relevant experience and knowledge and they have a proven record of successful execution for the current stage for this product. Besides leading a company introducing a new technology or product , they have understanding and means of accessing the US market, leaders in the asthma and sleep industrial, pursuing level 1 insurance codes etc.
The product is of value and has significant positive differentiators from the alternatives. It should be able to offer improved health care at lower cost.
The presentation shows a well thought out plan. It is worth reading.
KSX Price at posting:
1.5¢ Sentiment: LT Buy Disclosure: Held